Epocrates offers clinicians mobile downloads of current medical information
SAN MATEO, Calif. Epocrates has released downloadable education material that clinicians can access straight from their mobile devices to help keep themselves up-to-date on current medical information.
The information is called Epocrates Mobile Resource Centers and are authored and updated by recognized authorities in their field of medicine to help health care professionals stay current on diagnoses and treatments in certain areas.
Healthcare professionals can reference the centers for access to valuable information, including breaking news, research findings, conference highlights and related continuing medical education courses.
Resource centers that are currently available and continually updated with content selection and commentaries from industry authorities are:
- Attention deficit/hyperactivity disorder by Dr. Robb, associate professor of psychiatry and pediatrics at the Children’s National Medical Center
- Infection management by Dr. John Bartlett, former chief of infectious diseases and current professor of medicine at Johns Hopkins University
- Fibromyalgia by Dr. Stuart Silverman, professor of medicine and rheumatology at the University of California, Los Angeles, and Cedars-Sinai Medical Center
- Diabetes by Dr. Richard Jackson, assistant professor of medicine, Harvard Medical School
“It is so helpful to have the most important research and news for my field selected by a leading authority and delivered directly to my device. I even find myself quoting the information to my patients,” said Gregory Cooke of the Angleton Danbury Medical Center in Angleton, Texas. “For example, after reading Dr. Bartlett’s commentary on the prevalence of antibiotic resistance for urinary tract infections, I am more likely to send urine cultures as part of my treatment of UTIs.”
Mylan, Teva to begin shipping generic Requip
PITTSBURGH Mylan Pharmaceuticals has received approval from the Food and Drug Administration for its application for Ropinirole hydrochloride tablets and has announced it will begin shipping the drug immediately. Teva also announced the availability of its version of the tablets.
The drug is the generic form of GlaxoSmithKline’s Requip, which is used to treat moderate-to-severe primary restless leg syndrome. The generic will be available in 0.35 mg, 0.5 mg, 1 mg, 2 mg, 3 mg, 4 mg and 5 mg strengths.
According to IMS Health, the drug had sales of about $518 million in 2007.
Teva’s Q1 results show more than 25 percent sales increase
JERUSALEM Teva has released the results of its first quarter 2008, according to published reports.
Profits for the company fell by 57 percent to $147 million, but that was in large part to a $382 million acquisition charge the company suffered for buying the biotech company CoGenesys.
Teva did have a net income of $529 million, which beat the analysts’ forecast. Sales in North America increased by 27.3 percent for the quarter to $1.4 billion.
“The year is off to a strong start for Teva across all of our major businesses. It was a particularly outstanding quarter for Copaxone, which crossed the $500 million mark in in-market quarterly sales and became, for the first time, the number one global multiple sclerosis therapy,” said Shlomo Yanai, Teva’s chief executive officer.